Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.
Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.
ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.
The phase 3 AURA3 trial has failed to demonstrate a significant overall survival gain with second-line osimertinib versus platinum–pemetrexed in patients with advanced non-small-cell lung cancer carrying the EGFR T790M resistance mutation.
Patients undergoing chemoradiotherapy for unresectable stage III non-small-cell lung cancer could benefit from consolidation treatment with the PD-1 inhibitor pembrolizumab, suggest phase 2 study results.
The eXalt3 study has shown significantly better progression-free survival with ensartinib versus crizotinib in ALK inhibitor-naïve patients with ALK alteration-positive, advanced non-small-cell lung cancer.
Treatment-naïve patients with advanced nonsquamous non-small-cell lung cancer derive a significant progression-free survival survival with the addition of the PD-1 inhibitor sintilimab to chemotherapy, indicates the ORIENT-11 trial.
Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.
UK researchers have called for urgent action to be taken to avoid unnecessary cancer deaths as a result of delayed surgery due to the COVID-19 pandemic.
Two case studies reported in the Journal of Thoracic Oncology show that lung cancer patients receiving treatment with PD-1 inhibitors can present with atypical and severe skin manifestations when infected with SARS-CoV-2.
The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.
A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.
Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.
Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.